
Colzyx
Colzyx's WOUNDCOM is a new category of bioactive wound dressings. It mimics natural body mechanisms and, at the same time, combat bacterial infection.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
€1.0m | Convertible | ||
Total Funding | 000k |
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 25 % | (43 %) | (27 %) | - | - | - | 1 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 7 % | (40 %) | (1104 %) | - | - | (65 %) | (60 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Developer of bioactive wound care products intended to combat multidrug-resistant bacteria. The company's product utilizes molecules derived from human collagen in combination with a biomembrane to treat active and chronic wounds and accelerates wound healing while having an antibacterial effect, enabling customers to obtain rapid wound closure, and decrease bacterial wound and infections.
Keywords: Pharmaceuticals and Biotechnology, Antimicrobial Products, Biotechnology Company, Chronic Wounds Care, Healing Wound, Wound Care Product, Wound Care Supplies.